Specifically, the results uncovered that the proliferation rate of ASO-transfected GBM cells (ASO1_BCL2L1 and ASO3_BCL2L1) in response to pladienolide B treatment was significantly blunted compared with non-transfected cells treated with pladienolide B (Fig. 9n). The gene discussed is BCL2L1; the disease is glioblastoma.